Inhibikase Therapeutics, Inc. (IKT) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Inhibikase Therapeutics, Inc. (IKT), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Inhibikase Therapeutics, Inc., the average estimate for 2030 earnings per share is $0.21; 7 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Inhibikase Therapeutics, Inc. (IKT) forecast — frequently asked questions
What is the analyst price target for Inhibikase Therapeutics, Inc.?
Analysts covering Inhibikase Therapeutics, Inc. (IKT) have a consensus price target of $4.83, 250.0% above the current price of $1.38. Published targets range from $1.50 to $8.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Inhibikase Therapeutics, Inc.'s earnings?
The average analyst estimate for Inhibikase Therapeutics, Inc. (IKT) earnings per share in 2030 is 0.21, with individual estimates between 0.21 and 0.21.
How much revenue is Inhibikase Therapeutics, Inc. expected to make?
Analysts forecast Inhibikase Therapeutics, Inc. (IKT) revenue of $234.00M in 2030, based on 2 published estimates.
How many analysts cover IKT?
7 analysts contribute estimates for Inhibikase Therapeutics, Inc. (IKT). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.